'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome

被引:28
作者
van der Pool, A. E. M. [1 ]
Lalmahomed, Z. S. [2 ]
Ozbay, Y. [2 ]
de Wilt, J. H. W. [1 ]
Eggermont, A. M. M. [1 ]
Jzermans, J. N. M. [2 ]
Verhoef, C. [1 ]
机构
[1] Erasmus Univ MC, Daniel den Hoed Canc Ctr, Div Surg Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Erasmus Univ MC, Div Transplantat & Hepatobiliary Surg, NL-3008 AE Rotterdam, Netherlands
关键词
Synchronous metastases; metachronous metastases; two-stage resection; hepatic resection; colorectal liver metastases; LONG-TERM SURVIVAL; PROGNOSTIC-FACTORS; CLINICAL SCORE; CANCER; RECURRENCE; FOLFIRI;
D O I
10.1111/j.1463-1318.2009.02135.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim Approximately 25% of the patients with colorectal cancer already have liver metastases at diagnosis and another 30% will develop them subsequently. The features and prognosis of patients with synchronous and metachronus colorectal liver metastases, treated with primary resection first followed by partial liver resection were analysed. Method Curative staged resection of liver metastases was performed in 272 consecutive patients. Demographics, characteristics of the primary tumour and metastatic tumours, surgery-related data and outcome were analysed. Results Synchronous metastases were present in 105 (39%) patients and metachronous metastases in 167 (61%). More patients in the synchronous group had an advanced primary tumour (T3/T4 and/or node positivity), more than three liver metastases and bilobar distribution. A significantly higher percentage of patients in the synchronous group received neoadjuvant chemotherapy. The 5-year survival rate in the group of 272 patients was 38%. Patients with more than three metastases had a significantly worse survival rate. There were no differences in disease-free and overall survival rates between the synchronous and metachronous group. Conclusion Although patients with synchronous colorectal liver metastases may have poorer biological features, there was no difference in 5-year disease-free and overall survival compared with patients with metachronous metastases. This may be explained by the observation that patients in the synchronous group received significantly more neoadjuvant chemotherapy.
引用
收藏
页码:E229 / E235
页数:7
相关论文
共 26 条
[1]  
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[2]   Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J].
Allen, PJ ;
Kemeny, N ;
Jarnagin, W ;
DeMatteo, R ;
Blumgart, L ;
Fong, Y .
JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (01) :109-115
[3]   Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer [J].
Arru, Marcella ;
Aldrighetti, Luca ;
Castoldi, Renato ;
Di Palo, Saverio ;
Orsenigo, Elena ;
Stella, Marco ;
Pulitano, Carlo ;
Gavazzi, Francesca ;
Ferla, Gianfranco ;
Di Carlo, Valerio ;
Staudacher, Carlo .
WORLD JOURNAL OF SURGERY, 2008, 32 (01) :93-103
[4]   Survival of patients with synchronous and metachronous colorectal liver metastases -: is there a difference? [J].
Bockhorn, Maximilian ;
Frilling, Andreja ;
Fruehauf, Nils R. ;
Neuhaus, Jan ;
Molmenti, Ernesto ;
Trarbach, Tanja ;
Malago, Massimo ;
Lang, Hauke ;
Broelsch, Christoph E. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (08) :1399-1405
[5]   Trends in long-term survival following liver resection for hepatic colorectal metastases [J].
Choti, MA ;
Sitzmann, JV ;
Tiburi, MF ;
Sumetchotimetha, W ;
Rangsin, R ;
Schulick, RD ;
Lillemoe, KD ;
Yeo, CJ ;
Cameron, JL .
ANNALS OF SURGERY, 2002, 235 (06) :759-765
[6]   Liver anatomy: portal (and suprahepatic) or biliary segmentation [J].
Couinaud, C .
DIGESTIVE SURGERY, 1999, 16 (06) :459-467
[7]  
Dols Leonienke F C, 2009, Ned Tijdschr Geneeskd, V153, P490
[8]   Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest [J].
Falcone, Alfredo ;
Ricci, Sergio ;
Brunetti, Isa ;
Pfanner, Elisabetta ;
Allegrini, Giacomo ;
Barbara, Cecilia ;
Crino, Lucio ;
Benedetti, Giovanni ;
Evangelista, Walter ;
Fanchini, Laura ;
Cortesi, Enrico ;
Picone, Vincenzo ;
Vitello, Stefano ;
Chiara, Silvana ;
Granetto, Cristina ;
Porcile, Gianfranco ;
Fioretto, Luisa ;
Orlandini, Cinzia ;
Andreuccetti, Michele ;
Masi, Gianluca .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1670-1676
[9]   Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].
Fong, Y ;
Fortner, J ;
Sun, RL ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1999, 230 (03) :309-318
[10]   Long-term survival following resection of colorectal hepatic metastases [J].
Jaeck, D ;
Bachellier, P ;
Guiguet, M ;
Boudjema, K ;
Vaillant, JC ;
Balladur, P ;
Nordlinger, B .
BRITISH JOURNAL OF SURGERY, 1997, 84 (07) :977-980